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Introduction
We have reported the efficacy of continuous hemodiafil-
tration (CHDF) with a cytokine-adsorbing hemofilter in
the treatment of hypercytokinemia, such as severe sepsis,
septic shock, using a polymethylmethacrylate (PMMA)
membrane dialyzer (BK-2.1P®; Toray Medical Co Ltd,
Tokyo, Japan) [1], [2]. In 2013, a new PMMA hemofilter
(CH-1.8W®; Toray Medical Co Ltd, Tokyo, Japan) was
released in Japan. It is covered by Japanese medical insur-
ance for continuous renal replacement therapy.
Objectives
The aim of this study is to investigate the differences of
the efficacy as cytokine-adsorbing hemofilter between
BK-2.1P® and CH-1.8W® in the treatment of critically ill
patients.
Methods
Forty-eight consecutive patients with acute kidney injury
admitted to the intensive care unit (ICU) at the Univer-
sity of Yamanashi Hospital and treated with CHDF in the
period from July 2011 to January 2015 were entered in
this study. Twenty-four consecutive patients were treated
with BK-2.1P® between July 2011 and August 2013
(BK2.1P group). Twenty-four consecutive patients were
treated with CH-1.8W® between July 2013 and January
2015 (CH1.8W group). We compared changes in systolic
blood pressure, volume of urine, water balances and
blood level of interleukin-6 (IL-6) for 7 days from the
initiation of CHDF. In addition, we evaluated twenty-
eight day and ninety day survivals. Statistical analysis was
performed using the statistical software packages Prism
for Mac OS X (version 6.0f).
Results
The average ages in BK2.1P group and CH1.8W group
were 63.8 ± 14.8 and 65.1 ± 15.1, respectively. The
numbers of male were 16 and 17, respectively. APACHE
II scores were 29.3 ± 8.8 and 26.8 ± 6.4, respectively.
SOFA scores were 13.4 ± 3.3 and 12.3 ± 2.7, respec-
tively. There were no significant differences in the pre-
treatment clinical profiles between the two groups.
There were no significant differences of the changes in
systolic blood pressure, urine volume and water balances
per days following a week. At the initiation of CHDF,
the blood levels of IL-6 (log) (pg/mL) were 3.61 ± 1.01
and 3.94 ± 1.08, respectively. There were no significant
differences in IL-6 levels and the change ratios each day.
There were also no significant differences in twenty-
eight day and ninety day survivals. Ratios of the
observed ninety day survivals and the predicted survivals
calculated with APACHE II scores were 179.1% and
189.5%, respectively.
Conclusions
This study suggests that there were no differences in the
clinical course of critically ill patients received CHDF with
CH-1.8W and with BK-2.1P. We expect that the new
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hemofilter contributes to improvement of the survival of
the critically ill patients.
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